Alnylam Pharmaceuticals has proprietary lipid nanoparticle technology used in its FDA-approved RNA therapies. The biotech company claims that the messenger RNA Covid-19 vaccines from Moderna and Pfizer infringe on a patent covering this LNP technology.
Additive manufacturing, or 3D printing, has steadily become more mainstream in the medical device sector because of its ability to enable cost-effective, patient-centered device development, particularly in the fields of orthopedic, spine, maxillofacial, and pediatric surgery.
This webinar on April 6th will have perspectives from healthcare, the medical device sector, and the FDA to discuss how each are using 3D printing, the applications they are leveraging it for, how they can produce devices such as surgical tools more economically, the regulatory challenges they face, and how they can collaborate more effectively.
By Juan Pablo Segura Thursday, March 17, 2022 6:43 PM
The "Great Resignation" should spark a great transformation, where digital innovation is no longer a stop-gap but an integral part of any health care delivery strategy moving forward.
By Michael Schroeder Thursday, March 17, 2022 6:28 PM
With its two major announcements at the Global Health Conference & Exhibition in Orlando, the company signaled it is aiming to help providers access more in-depth, real-time patient data to improve clinical decision-making and care.
PathAI is partnering with Cleveland Clinic to digitize pathology slides and develop and improve PathAI's machine-learning algorithms that can drive research as well as improve patient outcomes in a clinical setting. Pramana is launching its digital pathology as a service product and has struck a 5-year commercial agreement with Mayo Clinic to digitize 5 million pathology slides.
Illumina Accelerator has invested in 68 companies so far, all of them startups developing genomics technologies. Seven startups comprise the latest cohort selected by the startup engine.
Alnylam Pharmaceuticals has proprietary lipid nanoparticle technology used in its FDA-approved RNA therapies. The biotech company claims that the messenger RNA Covid-19 vaccines from Moderna and Pfizer infringe on a patent covering this LNP technology.
By Stephanie Baum Thursday, March 17, 2022 1:09 PM
The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.
No comments